US BioDefense makes cardiac regeneration pact:
This article was originally published in Clinica
US BioDefense has formed a heart tissue regeneration deal with the University of Texas MD Anderson Cancer Center that gives it the priority option to review and license patent pending technology regarding the use of non-marrow stem cell for cardiac regeneration. "The use of these stem cells for myocardial regeneration may prove to be superior to other stem cell sources by circumventing the pain and anaesthesia complications associated with bone marrow aspiration procedures," said David Chin, CEO of the City of Industry, California-based firm.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.